Cas:12081-18-4 chloropalladium(1+),2-methanidylprop-1-ene manufacturer & supplier

Chemical Name:chloropalladium(1+),2-methanidylprop-1-ene

CAS.NO:12081-18-4

Synonyms:(2-Methylallyl)palladium(II) chloride dimer;Dichlorobis(2-methylallyl)dipalladium;Chloro(2-methylallyl)palladium(II) dimer

Molecular Formula:C₁₆H₂₈Cl₂Pd₂

Molecular Weight:504.14000

HS Code:

Physical and Chemical Properties:

Melting point:168.2-174.0ºC

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:501.96400

LogP:7.49940

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like (2-Methylallyl)palladium(II) chloride dimer chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Chloro(2-methylallyl)palladium(II) dimer physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2-Methylallyl)palladium(II) chloride dimer Use and application,Chloro(2-methylallyl)palladium(II) dimer technical grade,usp/ep/jp grade.

Related News: The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application. chloropalladium(1+),2-methanidylprop-1-ene manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. chloropalladium(1+),2-methanidylprop-1-ene supplier It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. chloropalladium(1+),2-methanidylprop-1-ene vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. chloropalladium(1+),2-methanidylprop-1-ene factory Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data.